Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

bloomberg.com - Madison Muller - FDA to Restrict Copycat Weight Loss Drugs Sold by Pharma Rivals
FDA to Restrict Copycat Weight Loss Drugs Sold by Pharma Rivals
Bloomberg

The US Food and Drug Administration said it would crack down on copycat weight loss drugs like those marketed by Hims & Hers Health Inc. The telehealth company said Thursday it's selling a deeply discounted version of Novo Nordisk A/S 's new weight…

seekingalpha.com - ONeil Trader - Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More
Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More
Seeking Alpha

Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and diabetes, outpacing Novo Nordisk, which faces a…

indianexpress.com - Ravi Dutta Mishra - India gains concession from US 'national-security' tariffs on metals, autos, pharma; agrees to buy soybean oil, industrial and agri goods
India gains concession from US 'national-security' tariffs on metals, autos, pharma; agrees to buy soybean oil, industrial and agri goods
The Indian Express

India has secured concessions on steel, aluminium, copper, pharma, cars and car parts that fall under Section 232 ‘national security' related tariffs, which only a few countries, such as the UK, Japan and South Korea, have received under the…

thehindubusinessline.com - F&O Strategy: Buy Sun Pharma Call
F&O Strategy: Buy Sun Pharma Call
BusinessLine

The stock of Sun Pharmaceutical Industries (₹1,695.10) has been moving in the ₹1,850-1,550 range since early 2025. Immediate resistance levels are ₹1,717 and ₹1,829. A close above the latter will trigger a fresh rally…

thehindubusinessline.com - FTA to boost Indian textiles, pharma, chemicals, agri exports as EU remains key trade partner: ICRA
FTA to boost Indian textiles, pharma, chemicals, agri exports as EU remains key trade partner: ICRA
BusinessLine

India 's recently concluded Free Trade Agreement (FTA) with the European Union is expected to deliver significant gains for several Indian sectors, including textiles, pharmaceuticals, chemicals, agriculture, leather, and marine products, as the EU…

marketbeat.com - Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - Here's Why
Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - Here's Why
MarketBeat

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s share price gapped down prior to trading on Friday. The stock had previously closed at $68.6950, but opened at $64.0750. Zealand Pharma A/S shares last traded at $64.0750, with a volume of 153…

seekingalpha.com - Anantdeep Singh - JD.Com: Priced For Collapse, Poised For 100% Upside (NASDAQ:JD)
JD.Com: Priced For Collapse, Poised For 100% Upside (NASDAQ:JD)
Seeking Alpha

JD.com (JD) is deeply undervalued, trading at ~8 PE despite 15% YoY revenue growth in Q3 and a $12B net cash position. JD's logistics arm has become a strategic moat, driving 24% YoY growth in Q3 and underpinning its dominance in last-mile delivery…

newsbytesapp.com - Dwaipayan Roy - US-India trade deal shields pharma exports from reciprocal tariffs
US-India trade deal shields pharma exports from reciprocal tariffs
NewsBytes

The joint statement issued by both nations highlights a roadmap for reciprocal trade, with a major focus on securing pharmaceutical supply chains and expanding market access for medical technology. This agreement is seen as a major step toward…

beincrypto.com - Mohammad Shahid - TrumpRx: Why Markets Care About This White House Drug Site
TrumpRx: Why Markets Care About This White House Drug Site
BeInCrypto

President Donald Trump this week launched TrumpRx, a government-backed platform aimed at lowering prescription drug prices for Americans paying out of pocket. While the announcement initially raised concerns about pricing pressure, financial…

yahoo.com - Ricardo Pillai - West Pharmaceutical Services, Inc. (WST): A Bull Case Theory
West Pharmaceutical Services, Inc. (WST): A Bull Case Theory
Yahoo!

We came across a bullish thesis on West Pharmaceutical Services, Inc. on TipRanks™'s YouTube Channel. In this article, we will summarize the bulls' thesis on WST. West Pharmaceutical Services, Inc.'s share was trading at $271.83 as of…

thehindu.com - The Hindu Bureau - 'Hyderabad crucial in leading India's biologics'
'Hyderabad crucial in leading India's biologics'
The Hindu

Hyderabad, major pharmaceutical hub in India, can help the country lead in biologics and next-generation therapy revolution by strengthening translational research, establishing specialised manufacturing clusters and forging multi-discipline…

thehindubusinessline.com - Simply Put: Biopharma Shakti
Simply Put: Biopharma Shakti
BusinessLine

Bhuvan and Sam are sharing views on the Budget announcements and Sam wants to know more about the Biopharma Shakti plan. As Bhuvan tracks pharma, Sam fires away at the topic. Sam: Biopharma Shakti, a plan to develop India as a biopharmaceutical hub…

deccanchronicle.com - Rachel Dammala - Women Dominate Honours At JNTU-H Convocation
Women Dominate Honours At JNTU-H Convocation
Deccan Chronicle

HYDERABAD: Women students topped academic honours at Jawaharlal Nehru Technological University Hyderabad (JNTU‑H) this year, even as the university placed artificial intelligence and emerging technologies at the centre of its academic push.

theatlantic.com - Nicholas Florko - The Real Winner of TrumpRx
The Real Winner of TrumpRx
The Atlantic

Nothing about TrumpRx is subtle. When you open up the government's new online drugstore, the first thing you see is a banner with giant text: “Find the world's lowest prices on prescription drugs.” Launched last night, TrumpRx allows…

globenewswire.com - F. Hoffmann-La Roche Ltd - Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
GlobeNewswire

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reducing disability progression in PPMS Fenebrutinib…

Receive a Daily briefing on Pharma Industry News

Get Started